Advanced search
Publication Cover
Expert Review of Vaccines Volume 8, 2009 - Issue 10
Submit an article Journal homepage
281
Views
19
CrossRef citations to date
0
Altmetric
Review

Peptide vaccines for patients with acute myeloid leukemia

Michael Schmitt Head of Clinical Stem Cell Transplantation and Cellular Therapy, Department of Internal Medicine III, University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany. [email protected]
,
Rosaely Casalegno-Garduño Department of Internal Medicine III, University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany. [email protected]
,
Xun Xu Department of Internal Medicine III, University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany. [email protected]
&
Anita Schmitt Department of Internal Medicine III, University of Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany. [email protected]
Pages 1415-1425 | Published online: 09 Jan 2014

References

  • Estey E, Döhner H. Acute myeloid leukemia (seminar). Lancet368, 1874–1907 (2006).
  • Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist14, 222–232 (2009).
  • Kantarjian H, O’Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer106, 1090–1098 (2006).
  • Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76, 2462–2465 (1990).
  • Schmid C, Schleuning M, Ledderose G et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol.23, 5675–5687 (2005).
  • Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood112, 4371–4383 (2008).
  • Greiner J, Guinn B, Döhner H et al. Leukemia-associated antigens (LAAs) are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res.14, 1–6 (2008).
  • Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia (AML) – definition of targets and current clinical protocols (review). Haematologica91, 1653–1661 (2006).
  • Sahin U, Türeci Ö, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA92, 11810–11813 (1995).
  • Greiner J, Ringhoffer M, Taniguchi M et al. RHAMM is a new immunogenic tumor-associated antigen overexpressed in acute and chronic myeloid leukemia. Exp. Hematol.30, 1029–1035 (2002).
  • Greiner J, Ringhoffer M, Taniguchi M et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML). Int. J. Cancer106, 224–231 (2003).
  • Chen G, Zhang W, Cao X et al. Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk. Res.29, 503–922 (2005).
  • Sherman L, Sleeman J, Herrlich P et al. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin Cell. Biol.6, 726–733 (1994).
  • Yang B, Zhang L, Turley EA. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J. Biol. Chem.268, 8617–8623 (1993).
  • Hamann KJ, Dowling TL, Neeley SP et al. Hyaluronic acid enhances cell proliferation during eosinopoesis through the CD44 surface antigen. J. Immunol.154, 4073–4080 (1995).
  • Assmann V, Kern HF, Elsässer HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin. Cancer Res.2, 1607–1618 (1996).
  • Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res.55, 3908–3914 (1995).
  • Crainie M, Belch AR, Mant MJ et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood93, 1684–1696 (1999).
  • Pilarski LM, Masellis-Smith A, Belch A et al. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leuk. Lymphoma14, 363–374 (1994).
  • Turley EA, Belch AJ, Poppema S et al. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood81, 446–453 (1993).
  • Hall CL, Yang B, Yang X et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell82, 19–26 (1995).
  • Wang C, Thor AD, Moore II DH et al. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin. Cancer Res.4, 567–576 (1998).
  • Zlobec I, Terracciano L, Tornillo L et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut57, 1413–1419 (2008).
  • Spicer AP, Roller ML, Camper SA et al. The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11. Genomics30, 115–117 (1995).
  • Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res.59, 4419–4426 (1999).
  • Savani RC, Cao G, Pööler PM et al. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J. Biol. Chem.276, 36770–36778 (2001).
  • Greiner J, Li L, Ringhoffer M et al. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood106, 938–945 (2005).
  • Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother.54, 685–693 (2005).
  • Dengler R, Munstermann U, Al-Batran S et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol.89, 250–257 (1995).
  • Fujiwara H, El Ouriaghli F, Grube M et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood103, 3076–3083 (2004).
  • Bories D, Raynal MC, Solomon DH et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell59, 959–968 (1989).
  • Yong AS, Szydlo RM, Goldman JM et al. Molecular profiling of CD34+ cells in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. Blood107, 205–212 (2006).
  • Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood88, 2450–2457 (1996).
  • Molldrem JJ, Lee PP, Wang C et al. A PR-1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res.59, 2675–2681 (1999).
  • Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest.111, 639–647 (2003).
  • Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology (Am. Soc. Hematol. Educ. Program)331–349 (2003).
  • Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PR-1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood104, 259 (2004) (Abstract).
  • Qazilbash MH, Wieder E, Thall PF et al. PR-1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response event-free survival. Blood110, 577 (2007) (Abstract).
  • Rezvani K. PR-1 vaccination in myeloid malignancies. Expert Rev. Vaccines7(7), 867–875 (2008).
  • Haber DA, Buckler AJ, Glaser T et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell61, 1257–1269 (1990).
  • Bergmann L, Miething C, Maurer U et al. High levels of Wilms’ tumor gene (WT-1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood90, 1217–1225 (1997).
  • Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT-1 peptide. Blood95, 286–293 (2000).
  • Maurer U, Weidmann E, Karakas T et al. Wilms tumor gene (WT-1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood90, 4230–4232 (1997).
  • Gaidzik VI, Schlenk RF, Moschny S et al.; German–Austrian AML Study Group. Prognostic impact of WT-1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German–Austrian AML Study Group. Blood113, 4505–4511 (2009).
  • Oka Y, Tsuboi A, Taguchi T et al. Induction of WT-1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT-1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101, 13885–13890 (2004).
  • Bellantuono I, Gao L, Parry S et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood100, 3835–3837 (2002).
  • Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT-1 product in patients with hematopoietic malignancies. Blood99, 3272–3279 (2002).
  • Schmid D, Heinze G, Linnerth B et al. Prognostic significance of WT-1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia11, 639–643 (1997).
  • Cilloni D, Messa F, Arruga F et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT-1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica93, 921–924 (2008).
  • Greiner J, Ringhoffer M, Taniguchi M et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int. J. Cancer108, 704–711 (2004).
  • Gaiger A, Reese V, Disis ML et al. Immunity to WT-1 in the animal model and in patients with acute myeloid leukemia. Blood96, 1480–1489 (2000).
  • Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT-1 and proteinase 3 in patients with acute myeloid leukemia. Blood100, 2132–2137 (2002).
  • Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT-1) peptide vaccination in patients with AML and MDS. Blood113, 6541–6548 (2009).
  • Mailander V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT-1 peptide in the absence of hematological or renal toxicity. Leukemia18, 165–166 (2004).
  • Schmitt M, Schmitt A, Rojewski M et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. Blood111, 1357–1365 (2008).
  • Giannopoulos K, Kowal M, Dmoszynska A et al. Peptide vaccination induces dynamic changes in CD4+ and CD8+ T cell subsets: report on the first peptide vaccination trial in patients with chronic lymphocytic leukemia (CLL). Blood112, 3159 (2008) (Abstract).
  • Greiner J, Schmitt A, Giannopoulos K et al. High-dose RHAMM-R3 peptide peptide vaccination for patients with vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Blood112, 2911 (2008) (Abstract).
  • Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR-1 and WT-1 peptide vaccination in patients with myeloid malignancies. Blood111, 236–242 (2008).
  • Wagner EM, Kuball J, Wattad M, Huber C, Heit W, Theobald M. Vaccination with WT-1 and PR-3 derived peptides in patients with AML/MDS and MUC1 peptides in patients with multiple myeloma – preliminary results. Blood108, abstract 4582 (2006).
  • Palucka AK, Laupeze B, Aspord C et al. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol.560, 105–114 (2005).
  • Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat. Immunol.2, 487–492 (2001).
  • Banchereau J, Schuler-Thurner B, Palucka AK et al. Dendritic cells as vectors for therapy. Cell106, 271–274 (2001).
  • Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med.179, 1109–1118 (1994).
  • Figdor CG, de Vries IJ, Lesterhuis WJ et al. Dendritic cell immunotherapy: mapping the way. Nat. Med.10, 475–480 (2004).
  • Kufner S, Fleischer RP, Kroell T et al. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol. Immunother.54, 953–970 (2005).
  • Cignetti A, Bryant E, Allione B et al. CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood94, 2048–2055 (1999).
  • Kohler T, Plettig R, Wetzstein W et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells18, 139–147 (2000).
  • Reichardt VL, Brossart P. Dendritic cells in clinical trials for multiple myeloma. Methods Mol. Med.109, 127–136 (2005).
  • Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukemia. Br. J. Hematol.133, 152–157 (2006).
  • Mocellin S, Semenzato G, Mandruzzato S et al. Part II: vaccines for haematological malignant disorders. Lancet Oncol.5, 727–737 (2004).
  • Li L, Giannopoulos K, Reinhardt P et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncol.28, 855–861 (2006).
  • Berneman ZN, Van de Velde A, Van Driessche A et al. Immunogenicity and antileukemic activity of dendritic cells electroporated with Wilms’ tumor WT-1 mRNA: a Phase I/II trial in acute myeloid leukemia. Blood112, 830 (2008) (ASH abstract).
  • Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist14, 240–252 (2009).
  • Burchert A, Neubauer A. Interferon a and T-cell responses in chronic myeloid leukemia. Leuk. Lymphoma46, 167–175 (2005).
  • Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature418, 252–258 (2002).
  • Widera G, Austin M, Rabussay D et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol.164, 4635–4640 (2000).
  • Grunebach F, Muller MR, Brossart P. New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer. Immunol. Immunother.54, 517–525 (2005).
  • Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
  • Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine22, 3136–3143 (2004).
  • Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115, 739–746 (2005).
  • Weber G, Karbach J, Kuci S et al. WT1 peptide specific T cells generated from peripheral blood of healthy donors: possible implication for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia (2009) (Epub ahead of print).
  • Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother.54, 685–693 (2005).
  • Li L, Schmitt A, Reinhardt P et al. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immun.3, 8 (2003).
  • Schmitt A, Li L, Giannopoulos K et al. Quantitative expression of Toll-like receptor-2, -4 and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion48, 861–870 (2008).
  • Hus I, Schmitt M, Tabarkiewicz J et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells towards an anti-leukemia response. Leukemia22, 1007–1017 (2008).
  • Hus I, Roliński J, Tabarkiewicz J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia19, 1621–1627 (2005).
  • Berneman ZN, Velde AV, Driessche AV et al. Immunogenicity and antileukemic activity of dendritic cells electroporated with Wilms’ Tumor WT1 mRNA: a Phase I/II trial in acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts)112, 830 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.